Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
44
Not yet recruiting, industry sponsors, Neurology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting120
- Completed845
44 trials
Showing 1 to 25, recently updated first.
- A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).Not yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07883590 · 32 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: LY3873862; CYP450 Drug Cocktail and 1 more · For: Amyotrophic Lateral Sclerosis; Cytochrome P-450 Enzyme System
Sites: San Francisco, California; Aurora, Colorado; Washington D.C., District of Columbia · 7 sites in all
Orca Biosystems, Inc.Industry
NCT06900192 · 10 participants (planned) · Start Mar 2027 · Primary completion Jun 2028
Drug: Orca-Q; myeloablative regimen and 1 more · For: Primary Progressive Multiple Sclerosis; Multiple Sclerosis; Multiple Sclerosis, Primary Progressive
- Clinical Trial of GenSci136 in Patients With Myasthenia GravisNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07936084 · 72 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: GenSci136 for injection · For: Patients With MG (gMG and oMG)
Sites: Shanghai, China
- A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple SclerosisNot yet recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07749157 · 85 participants (planned) · Start Dec 14, 2026 · Primary completion Feb 28, 2031
Drug: RO7845860 · For: Relapsing Multiple Sclerosis
- A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)Not yet recruiting
Sachi Bioworks Inc.Industry
NCT07906665 · 40 participants (planned) · Start Jan 22, 2027 · Primary completion Mar 1, 2028
Drug: NI112; Placebo · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older AdultsNot yet recruiting
PfizerPfizer (PFE)
NCT07897708 · 98 participants (planned) · Start Nov 17, 2026 · Primary completion Mar 17, 2027
Drug: PF-08161842; Placebo for PF-08161842 · For: Alzheimer Disease
- A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBSNot yet recruiting
Nuwacell Biotechnologies Co., Ltd.Industry
NCT07896187 · 12 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: NCR201 · For: PARKINSON DISEASE (Disorder); Cell Therapy; Human Induced Pluripotent Stem Cells and 3 more
Sites: Beijing, China
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseaseNot yet recruiting
CRISPR TherapeuticsIndustry
NCT07804004 · 220 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 30, 2029
Drug: CTX112 · For: Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and 2 more
AbelZeta Inc.Industry
NCT07825389 · 119 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: C-CAR168 · For: Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS) and 6 more
Sites: Gilbert, Arizona; La Jolla, California
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07857135 · 140 participants (planned) · Start Oct 3, 2026 · Primary completion Feb 3, 2029
Drug: SYS6088; Regorafenib and 1 more · For: Advanced/Metastatic Solid Tumors
Rinri TherapeuticsIndustry
NCT07032038 · 20 participants (planned) · Start Sep 2027 · Primary completion May 2029
Drug: Otic neural progenitors · For: Sensorineural Hearing Loss; Presbyacusis; Auditory Neuropathy
Sites: Birmingham, United Kingdom; Cambridge, United Kingdom; London, United Kingdom
- 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's PatientsNot yet recruiting
MTI Biotech IncIndustry
NCT06432166 · 48 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 30, 2028
Drug: 2-hydroxybenzylamine acetate · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Nashville, Tennessee
- An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia GravisNot yet recruiting
Shanghai Lanyi Therapeutics Co., Ltd.Industry
NCT07818291 · 18 participants (planned) · Start Sep 15, 2026 · Primary completion Dec 31, 2027
Drug: EA5; EA5 and 1 more · For: Generalized Myasthenia Gravis (gMG)
Sites: Beijing, China; Shanghai, China
- A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBNNot yet recruiting
Guangzhou Magpie Pharmaceuticals Co., Ltd.Industry
NCT04667013 · 16 participants (planned) · Start Sep 1, 2028 · Primary completion Mar 31, 2029
Drug: Tetramethylpyrazine nitrone (TBN) tablet / Placebo · For: Healthy
- Repeat Intracerebroventricular Injections of RB-ADSC in Subjects Previously Treated in RBI Protocol RB-ADSC-02Not yet recruiting
Regeneration Biomedical, Inc.Industry
NCT07373067 · 9 participants (planned) · Start Sep 2026 · Primary completion Sep 2028
Drug: RB-ADSC · For: Alzheimer Disease
- A Basket Study of CTA313 in Participants With Active Autoimmune DiseasesNot yet recruiting
Imviva BioIndustry
NCT07783269 · 81 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: CTA313 UCAR T Cell Infusion · For: Systemic Lupus Erthematosus (SLE); Progressive Multiple Sclerosis (PMS); Autoimmune Encephalitis
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)Not yet recruiting
Eisai Inc.Eisai
NCT07768592 · 32 participants (planned) · Start Oct 15, 2026 · Primary completion May 6, 2030
Drug: E2511; Donepezil · For: Alzheimers Disease
Shenzhen MagicRNA Biotechnology Co., LtdIndustry
NCT07556120 · 6 participants (planned) · Start Dec 31, 2026 · Primary completion May 31, 2027
Drug: HN2301 injection · For: Generalized Myasthenia Gravis
Sites: Hefei, China
- Safety Study of XT-150 in Participants With ALSNot yet recruiting
Xalud Therapeutics, Inc.Industry
NCT06704347 · 8 participants (planned) · Start Mar 2027 · Primary completion Jun 2028
Drug: XT-150 · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Phoenix, Arizona; Baltimore, Maryland; Boston, Massachusetts · 4 sites in all
Q Therapeutics, Inc.Industry
NCT02478450 · 30 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Q-Cells · For: Amyotrophic Lateral Sclerosis
- A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved OcrevusPivotal-lookingNot yet recruiting
Polpharma Biologics International AGIndustry
NCT07606521 · 222 participants (planned) · Start Oct 2026 · Primary completion Dec 2027
Drug: US-Ocrevus; PB018 and 1 more · For: Multiple Sclerosis
Shanghai Jeyou Pharmaceutical Co., Ltd.Industry
NCT07601386 · 18 participants (planned) · Start May 10, 2026 · Primary completion Jun 20, 2027
Drug: JMKX000189 · For: CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sites: Shanghai, China
- Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's PatientsNot yet recruiting
Cenna Biosciences Inc.Industry
NCT07568041 · 54 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 2027
Drug: 8M2D; Placebo · For: Alzheimer's Disease (AD)
- A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 MutationsNot yet recruiting
Shanghai Vitalgen BioPharma Co., Ltd.Industry
NCT07414290 · 17 participants (planned) · Start May 25, 2026 · Primary completion Sep 1, 2027
Drug: VGN-R08b 4.2×10^13 vg; VGN-R08b 8.4×10^13 vg and 1 more · For: Parkinson Disease (PD)
Sites: Changsha, China
iRegene Therapeutics Co., Ltd.Industry
NCT07550374 · 10 participants (planned) · Start May 2026 · Primary completion Apr 2028
Drug: NouvNeu001 injection · For: Parkinson's Disease (PD)
Sites: Hefei, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.